Constella, containing the active ingredient linaclotide, is a medication commonly used to help with managing the symptomatic burden of specific functional gastrointestinal conditions. It is applied across domains where additional symptomatic support is needed. It is relevant for easing symptoms in adults with Irritable Bowel Syndrome with Constipation (IBS-C) and Chronic Idiopathic Constipation (CIC), and may assist with managing functional constipation in older children. Linaclotide is applied in addressing symptom clusters that may become intense or disruptive, such as abdominal discomfort, cramping, and feelings of incomplete bowel movements. These are symptoms that often interfere with daily functioning. The medication contributes to easing the overall symptom load and helps maintain a sense of stability when symptoms are more noticeable. This supportive relief is commonly used when short-term symptomatic assistance is needed during difficult episodes. As a component of symptomatic management, it supports patients during episodes of heightened discomfort.

“The medication contributes to easing the overall symptom load.”

Quick Fact: Relief for Physical Discomfort

Regulatory References

1. NIH MedlinePlus overview

Who can and cannot use Constella? — Official Regulatory Information

Eligibility scope	Statement
Populations for whom use is allowed	Adults (18 years and older) are the primary approved user group. Specific regulatory indications also exist for pediatric patients mathbfgeq 6 or mathbfgeq 7 years of age for certain conditions in the US and Canada.
Populations for whom use is not recommended	Use is not recommended for patients with chronic inflammatory intestinal conditions (such as Crohn's disease or ulcerative colitis), as clinical study data is lacking. Use during pregnancy is preferably avoided as a precautionary measure due to limited data.
Populations for whom use is contraindicated	Constella is contraindicated in patients less than 2 years of age due to the risk of serious dehydration. It is also prohibited for patients with a known or suspected mechanical gastrointestinal obstruction or a known hypersensitivity to linaclotide.
Age-related eligibility rules	Pediatric patients mathbf< 2 years are contraindicated. In the EU and for general use in Canada, the medicine should not be used in children and adolescents under 18 years due to insufficient safety and efficacy data.
Condition-specific eligibility rules	No dose adjustment is required for patients with hepatic or renal impairment. However, patients prone to a disturbance of water or electrolyte balance (e.g., elderly, those with cardiovascular conditions) require careful monitoring.
Lactation eligibility status	Use during breastfeeding is acceptable as minimal systemic absorption means exposure to the infant is not expected; linaclotide was not detectable in breast milk samples.

---

Eligibility Classifications (High-Level)

Eligibility Severity Classification	Regulatory Basis	Eligibility-Context Constraints
Contraindicated (Absolute Prohibition)	Boxed Warning (US FDA), Contraindications (EMA SmPC)	Age <2 years, Mechanical GI Obstruction, Hypersensitivity
Not Recommended/Avoid Use (Conditional Prohibition)	Special Warnings (EMA SmPC)	Chronic Inflammatory Intestinal Conditions, General Pediatric Use <18 years
No Adjustment Required (Use Permitted)	Special Populations (EMA SmPC)	Hepatic Impairment, Renal Impairment

---

Connection to the overall eligibility profile

Official regulatory documents define the permissible user base by establishing strict absolute contraindications based on age and physical obstruction and specify the eligible adult population. The framework imposes conditional restrictions for pediatric, elderly, and co-morbid populations where use is either not established or requires additional caution. This structured classification dictates the appropriate use of the medicine.

Interactions with other medicines and products

The interaction profile for this medicine is primarily shaped by its minimal absorption into the bloodstream, meaning systemic drug interactions, such as those involving the cytochrome P450 enzyme system, are not anticipated. Due to this local action within the gastrointestinal tract, formal drug-drug interaction studies have not been conducted.

The main interaction-related concern documented in official labeling is the potential for severe or prolonged diarrhea, which can affect the absorption of other oral medications taken concurrently. This risk leads to specific warnings for co-administration with particular classes of medicines:

Affected Oral Product Category	Practical Regulatory Implication
Medicines with a Narrow Therapeutic Index	Caution is advised, as reduced absorption may lower the efficacy of medicines like levothyroxine (thyroid hormone).
Oral Contraceptives	Efficacy may be reduced; the use of an additional barrier contraceptive method is recommended to prevent possible failure.
Proton Pump Inhibitors (PPIs), Laxatives, NSAIDs	Concomitant use may increase the risk of developing diarrhea, and caution should be exercised when co-administering.

In all cases where severe or prolonged diarrhea occurs, the absorption of any co-administered oral product may be compromised. Healthcare professionals should carefully monitor patients when these combinations are used.

The mechanism of Linaclotide is highly localized and acts via a dual physiological process initiated by a single molecular interaction within the gut.

Targeted Activation of the GC-C Receptor

Linaclotide is a selective agonist that binds to and stimulates the Guanylate Cyclase-C (GC-C) receptor on the apical surface of the intestinal epithelium. This primary molecular action initiates two distinct downstream signaling cascades, ensuring the effect is mechanically restricted to the gastrointestinal tract due to the drug’s minimal systemic exposure.

Mechanism for Accelerated Gastrointestinal Transit

GC-C receptor activation increases intracellular levels of cyclic Guanosine Monophosphate (cGMP), which subsequently opens the CFTR ion channel. This sequence drives the active secretion of chloride and bicarbonate ions and water into the bowel lumen. The resulting increased fluid volume accelerates the propulsion of material within the colon.

Modulation of Visceral Sensation

The elevated levels of extracellular cGMP resulting from receptor agonism diffuse to affect the activity of local colonic nociceptors (pain-sensing nerves). This mechanism modulates the transmission of afferent nerve signals, decreasing the sensitivity of visceral afferent nerve endings, and contributing to the functional modulation of visceral sensation within the intestinal wall.

Constella (linaclotide) is strictly administered via the oral route as a hard capsule. The medicine is taken once daily and must be consumed on an empty stomach, specifically at least 30 minutes before the first meal of the day, a key condition for proper usage.

---

Standard Labeled Dosing Regimens

Indication	Adult Standard Dose	Pediatric Standard Dose
IBS-C	290 micrograms (mcg) once daily	145 mcg once daily (ages 7 and older)
CIC	145 mcg once daily (72 mcg option available)	72 mcg once daily (Functional Constipation, ages 6–17)

---

Administration Context and Rules

The capsule must be swallowed whole and must not be crushed or chewed. Instructions allow for opening the capsule and mixing the inner beads with a small amount of water or applesauce for immediate consumption if swallowing is difficult.

Treatment is typically a long-term course, which requires healthcare professionals to periodically assess the need for continuation. In the event of a missed dose, the instruction is to skip the missed dose entirely and resume the regimen by taking the next scheduled dose at the regular time. It is directed not to take two doses simultaneously. Dosing adjustments for older adults or those with kidney or liver impairment are generally not required.

Research evidence / Overview of studies

This section outlines the available research on the investigation of the drug in conditions including various anxiety disorders and neuropathic pain.

---

Research on Anxiety Disorders

Generalized Anxiety Disorder (GAD)

Studies consistently examined the drug as a short-term approach for Generalized Anxiety Disorder (GAD). A key meta-analysis described results relevant to symptoms of excessive worry and tension compared to placebo.

• Study Design: Most evidence is derived from placebo-controlled randomized clinical trials (RCTs).
• Time to Findings: Studies noted findings suggesting potential changes in symptoms within 1-2 weeks.
• Withdrawal: The discontinuation phase of the trials evaluated the potential for withdrawal symptoms upon stopping the medication.

Social Anxiety Disorder (SAD)

The evidence for its use in treating Social Anxiety Disorder (SAD) was also collected in studies that included other first-line agents.

• Efficacy: Research examined the drug's influence on measures related to performance anxiety and avoidance behaviors.

---

Research on Chronic Neuropathic Pain

Research has explored whether the drug influenced measurements of pain levels and function in patients with chronic neuropathic pain.

• Pain Reduction: One Phase III trial analyzed the difference in pain scores over a 12-week period. This trial focused on post-herpetic neuralgia and painful diabetic neuropathy.

Common questions about Constella (FAQ)

---

Q: What is Constella (linaclotide) used to treat?

Constella is used to treat Irritable Bowel Syndrome with Constipation (IBS-C) and Chronic Idiopathic Constipation (CIC) in adults. The medicine belongs to a class of medications called guanylate cyclase-C (GC-C) agonists. Regulatory documents indicate its action is intended to increase bowel movements and ease abdominal symptoms associated with these conditions.

---

Q: How does Constella work to help with constipation?

Constella works by mimicking a natural compound in the body, which then activates specific receptors in the lining of the intestine. According to official product information, this process helps increase the secretion of fluid into the intestines and speeds up the movement of the gut. This dual action is intended to make stools softer and facilitate bowel movements, according to the official product information.

---

Q: Can I take Constella with other medications?

Regulatory information indicates that Constella may be taken with many other medicines. However, it is important to check the official product details, as some medications might affect the stomach or intestines and could potentially alter Constella's effect. If you have concerns about specific medications, it is recommended to discuss them with a healthcare professional.

---

Q: What should I do if I miss a dose of Constella?

Official product information suggests that if a dose is missed, individuals should skip that dose and take the next dose at the regular time. The regulatory documents advise against taking two doses at the same time to make up for a forgotten dose. Consistency in taking the medication is generally considered important for this type of treatment.

---

Q: Can Constella be taken with or without food?

Studies and official information indicate that Constella should be taken once daily on an empty stomach, at least 30 minutes before the first meal of the day. This specific timing is listed in the regulatory documents as the recommended way to use the medication for its intended effect.

How to Store and Dispose of Constella? (Linaclotide)

Official regulatory documents define strict requirements for the storage and disposal of Constella capsules.

Storage Requirements

Condition	Requirement
Temperature	Do not store above 30 C (86°F).
Moisture	Keep the bottle tightly closed to protect from moisture.
Container Integrity	Keep the desiccant canister(s) in the original, child-resistant bottle.
Stability	Use capsules within 18 weeks after first opening the bottle.
Prepared Medicine	Do not store the bead-applesauce or bead-water mixture for later use; administer immediately.

Disposal and Protection

The medicine must be kept out of the reach and sight of children. Disposal of any unused or expired Constella or waste material should be performed strictly in accordance with local governmental and pharmaceutical waste requirements.